CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
AI Briefing
- • Researchers developed CFTX-2034, a SSTR5 agonist, for post-bariatric hypoglycemia treatment using Confo Therapeutics' tech.
- • CFTX-2034 shows promise in preclinical research for life-threatening hypoglycemic episodes.
- • The treatment targets post-bariatric hypoglycemia, a common complication of bariatric surgery.
Source Summary
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist developed using the company’s proprietary technology platform for the treatment of life-threatening hypoglycemic episodes associated with post-bariatric hypoglycemia (PBH).
Advertisement